COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature
- 31 July 2020
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 152, 102991
- https://doi.org/10.1016/j.critrevonc.2020.102901
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNature Communications, 2020
- Towards modern anticancer agents that interact with tubulinEuropean Journal of Pharmaceutical Sciences, 2019
- Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancerAIDS, 2018
- Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the LiteratureDrug Safety, 2018
- Nivolumab combined with ruxolitinib: antagonism or synergy?Annals Of Oncology, 2018
- Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case reportActa Oncologica, 2018
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant DataJama-Journal Of The American Medical Association, 2015
- FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman DiseaseClinical Cancer Research, 2015
- The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cellsInternational Journal of Oncology, 2015
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011